Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.33 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12653259 | 0.75 | SSTR4 (0.41) | CDK2SSTR4L3MBTL1CLK4 | |
| SCHEMBL23107176 | 0.74 | TSHR (0.38) | CDK2KDM4EALDH1A1L3MBTL1KDM4D | |
| SCHEMBL22337979 | 0.72 | SSTR4 (0.39) | CDK2SSTR4KDM4EALDH1A1CLK4 | |
| SCHEMBL23351005 | 0.72 | NUDT1 (0.38) | SMN1; SMN2SSTR4KDM4EALDH1A1 | |
| SCHEMBL19456714 | 0.72 | L3MBTL1 (0.38) | SSTR4KDM4EL3MBTL1CLK4 | |
| SCHEMBL12618988 | 0.71 | PDE4A (0.39) | CDK2SMN1; SMN2KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL22367851 | 0.71 | L3MBTL1 (0.36) | CDK2PIK3CGELANESMN1; SMN2L3MBTL1 | |
| Hydrochloric Acid SCHEMBL16241469 | 0.70 | L3MBTL1 (0.37) | SSTR4KDM4EL3MBTL1CLK4 | |
| SCHEMBL16061286 | 0.70 | PIK3CG (0.45) | PIK3CGSMN1; SMN2KDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL1795034 | 0.70 | CYP3A4 (0.40) | CDK2ADRA1AHPGDCLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10675268-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | CENTREXION THERAPEUTICS CORPORATION (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190269650-A1 | NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2019-09-05 | — | — | US | disclosed |
| US-10166214-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | CENTREXION THERAPEUTICS CORPORATION (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180092880-A1 | SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2018-04-05 | — | — | US | disclosed |
| US-20180092880-A1 | SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2018-04-05 | — | — | US | disclosed |
| EP-2997021-B1 | NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | CENTREXION THERAPEUTICS CORP (US) | 2017-12-20 | — | — | EP | disclosed |
| US-9789082-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | CENTREXION THERAPEUTICS CORPORATION (US) | 2017-10-17 | — | — | US | disclosed |
| US-9789082-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | CENTREXION THERAPEUTICS CORPORATION (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170014381-A1 | NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2017-01-19 | — | — | US | disclosed |
| US-20170014381-A1 | NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2017-01-19 | — | — | US | disclosed |
| US-9371282-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | CENTREXION THERAPEUTICS CORPORATION (US) | 2016-06-21 | — | — | US | disclosed |
| US-9371282-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | CENTREXION THERAPEUTICS CORPORATION (US) | 2016-06-21 | — | — | US | disclosed |
| WO-2014184275-A1 | NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-20 | — | — | WO | disclosed |
| US-20140343065-A1 | New Somatostatin receptor subtype 4 (SSTR4) agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092880-A1 | SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | SSTR4, SSTR3, SSTR1 | CDK2 3509/4885PIK3CG 2211/4885ELANE 4239/4885 |
| US-20190269650-A1 | NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | SSTR4, SSTR3, SSTR1 | CDK2 3354/4885PIK3CG 1942/4885ELANE 4262/4885 |
| US-10675268-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | SSTR4, SSTR3, SSTR1 | CDK2 3509/4885PIK3CG 2211/4885ELANE 4239/4885 |
| US-20170014381-A1 | NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | SSTR4, SSTR3, SSTR1 | CDK2 3354/4885PIK3CG 1942/4885ELANE 4262/4885 |
| US-10166214-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | SSTR4, SSTR3, SSTR1 | CDK2 3509/4885PIK3CG 2211/4885ELANE 4239/4885 |
| US-20140343065-A1 | New Somatostatin receptor subtype 4 (SSTR4) agonists | SSTR4, SSTR3, SSTR1 | CDK2 3354/4885PIK3CG 1942/4885ELANE 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.